GluSense

Company Overview

Snapshot

Founded in April 2007, GluSense operated with 1–10 employees, developing advanced medical devices. The company secured a grant in February 2017, contributing to its total capital raised of $7 million across three funding rounds from three investors.

Business overview

GluSense specializes in developing the Glyde CGM, a miniature, implantable continuous glucose sensor designed to significantly improve the quality of life for patients with diabetes. This biosensor detects glucose and transmits continuous optical signals to an external unit or smartphone for over a year. The company operates within the Health Tech & Life Sciences sector, focusing on medical devices, digital healthcare, and patient remote monitoring, serving markets in China and the United States.

Strategic signal

In February 2017, GluSense received a $2 million grant, which was highlighted by industry publications like Drug Delivery Business and FierceBiotech. This non-equity funding underscored external validation for GluSense's innovative injectable glucose sensor technology, signaling confidence in its potential to advance diabetes management solutions.

Company Intelligence Q&A

What is GluSense's primary product?

GluSense's primary product is the Glyde CGM, a miniature, implantable continuous glucose sensor designed to transmit glucose values to an external unit or smartphone for over a year.

When was GluSense founded?

GluSense was founded in April 2007.

What was a significant funding event for GluSense?

In February 2017, GluSense received a $2 million grant, as reported by Drug Delivery Business and FierceBiotech.

What is the current status of GluSense?

GluSense is currently non-active, having ceased operations in February 2021.